New Insights on the Science of HMOs Part 2: How HMOs Benefit Brain Development and Health

By:  Talking Nutrition Editors

 

Early life nutrition has implications for future health: experts weigh in  

  • Human milk oligosaccharides (HMOs) are an important bioactive component of human breastmilk and may be a key component of the cognitive benefits associated with breastfeeding.1  
  • The first 1000 days are a critical window for brain development.2 Emerging preclinical evidence suggests that HMOs may exert both direct and indirect influence on both brain development and health.3, 4  
  • In this article, Dr. Louise Kristine Vigsnæs, Head of Biology, and Dr. Stine Dam Jepsen, Scientist at DSM, provide insights on how HMOs may influence brain development and health.

HMOs are a bioactive component of breastmilk that appear to positively impact the brain

Research over the last several decades reveals that certain aspects of cognitive development  are superior in breastfed infants as compared to those that are formula-fed.5, 6 A review published in 2020 by Al-Khafaji et al. assessing the potential impact of human milk oligosaccharides (HMOs) on the gut-brain axis suggests that the cognitive benefits of breastfeeding may be due, in part, to HMOs found in breastmilk.1 The potential link between the HMOs in breastmilk and coginitive development is supported in other literature as well.3,4  

Until recently, the presence of HMOs in infant formula was very limited and a key differentiating factor between breastmilk and infant formula composition, which may help explain why breastfed infants experience a number of unique, positive health outcomes.7, 8 HMOs are the third largest solid component of human breastmilk. While milk oligosaccharides are present in cow’s milk, they are much more abundant and structurally diverse in human milk.9  

The function of individual HMOs is linked to their structure and high abundance in breast milk, and the potential impact of certain HMOs on brain health is likely dependent on both the structure of the HMO and the amount provided.Emerging data from preclinical models and an infant observational study suggest a role of HMOs in brain development and cognition,10-15 with some preclinical data indicating that the impact on brain might be influenced by the gut microbiota,11,12 illustrating the functionality of the gut-brain axis.  

Dr. Louise Vigsnæs, Head of HMO Biology, and Dr. Stine Dam Jepsen, Scientist at DSM, answer questions on the role of HMOs and brain health 

Why are the first 1000 days so important for brain development? 

The brain is a complex and unique organ that develops and changes throughout life. In the early years – ranging from conception throughout the first two years of life – the brain goes through the biggest transformation.2 While the development of the brain is a lengthy process that continues into adulthood, growth acceleration and its ability to grow are highest within the first 1,000 days.16 Different parts of the brain and different cognitive functions develop along different timelines, and in these periods, the brain is particularly susceptible to environmental stimuli. During phases of rapid brain development, suboptimal nutrition, malnutrition or damage from external factors can have irreversible and lifelong consequences.2,16,17  

How does gut health affect brain health generally, even beyond infants?  

We understand a great deal about this based on both animal models and human associational data. The gut-brain axis is a well-described bidirectional communication pathway.18  Recently, the gut immune system was recognized as a contributor to this communication system.19 In this sense, the health status of the gut contributes to the interaction between the immune system and the brain, which has implications for brain health.19 

A favourable balance of beneficial bacteria in the GI tract is desirable for overall health.20,21 Emerging data in animal models suggest that, in the gut, a balanced immune response supports pathogen resistance and helps reduce unnecessary inflammation.22 When the balance of microbiota in the gut is disturbed, brain health can be affected.23,24 As an example, inflammation in the gut releases immunity-related molecules such as cytokines, which can enter the systemic circulation, travel to the brain, and potentially impact brain health.25 In addition, the gut microbiota produces neurotransmitters that can cross talk with the nervous system.26 However, if the gut microbiota is not in balance, the production of neurotransmitters change and can impact brain health.26 Dysbiosis and inflammation in the gut may be linked to certain neurologic conditions.27-30 These associations suggest an interplay between the gut and neurologic regulation, which upon further investigation may provide evidence of the importance of the gut in brain health. 

To sum up, the health status in the gut appears to be tightly linked to the health status of the brain. 

The role of HMOs in brain development and health 

Recent studies suggest certain HMOs may have direct or indirect influence on brain development and health. 2’FL is the most commonly used HMO in infant formula and preclinical studies show potential positive outcomes in brain health and function.11,31  Sialylated HMOs, including the most commonly studied 3’SL and 6’SL, may have the potential to affect brain health based on preclinical3,12,13,32 and observational studies.33 Drs. Vigsnæs and Jepsen provided additional insight into how HMOs might exert their influence on the brain.  

How do HMOs affect the developing brain? Do all HMOs have a similar impact? 

While the science continues to evolve in this area, the exact mechanisms through which HMOs affect brain health are emerging. Individual HMOs have unique properties, and we could therefore speculate that different HMOs would also have varying effects on brain health. An observational study found that breastfed infants have higher amounts of sialic acids in their brain tissue compared to formula-fed infants.33 In addition, a preclinical study has shown that animals fed with HMOs containing sialic acid had higher amounts of sialic acid in their brain tissue compared to the control group.12 This could indicate that sialylated HMOs are utilized as building blocks for the brain.  

Fucosylated HMOs may also impact brain development, as they have been shown to be broken down by the gut bacteria to short chain fatty acids (SCFAs), which are metabolites that may indirectly affect brain health.1,34,35 An association infant study by Berger et al. found that infants receiving higher concentrations of the fucosylated HMO 2’FL in breast milk at one month of age have improved cognitive development at 2 years of age, linking early HMO ingestion to cognitive development.15  Preclinical studies in animals have found that feeding fucosylated HMOs impact memory and cognition and improve learning and long term potentiation.4,10,11 These studies suggest an emerging role for HMOs in the field of brain health and development. 

The gut-brain-immune axis

New research indicates we should add an immune component to the gut-brain axis, creating the gut-brain-immune axis.1, 36 Drs. Vigsnæs and Jepsen explain how the brain, through cross-talk, may influence the gut and immune systems.  

How does the brain influence the gutmicrobiome and the immune system?

As before, animal models give us insights here. The brain can affect the gut, its microbiota, and the gut immune system through regulation of gut motility, secretions in the gut (e.g. gastric acid or mucus) and gut permeability.18,37 For example, brain health can affect the integrity of the gut barrier, seen in data illustrating that chronic psychological stress can result in increased intestinal permeability; this in turn can trigger the immune system to initiate an inflammatory response.38 In addition, the brain regulates the release of bioactive molecules into the gut, affecting the microbiota as well as the gut immune cells.37 

HMOs may have the potential to positively impact the gut-brain-immune axis in a variety of ways. While the body of evidence in these areas continues to grow and evolve, the review by Al-Khafaji et al. provides an excellent overview of the evidence to-date. Next-generation HMOs are part of our exciting innovation roadmap, with four new HMOs becoming available this year for innovation trials to further catalyze the already fast-growing HMO market. 

At DSM, we know life is healthier when it's supported from the beginning. That's why we're committed to delivering high-quality, insight-driven, innovative nutritional solutions at every stage of your product's development. This takes more than ingredients. It takes a partner. Contact us to explore how we can help your business. 

Published on

12 February 2021

Share

8 min read

References

  1. Bode L. Human milk oligosaccharides: every baby needs a sugar mama. Glycobiology. 2012;22(9):1147-1162.
  2. Saavedra JM, Dattilo AM. Early development of intestinal microbiota: implications for future health. Gastroenterol Clin North Am. 2012;41(4):717-731.
  3. Al-Khafaji AH, Jepsen SD, Christensen KR, Vigsnæs LK. The potential of human milk oligosaccharides to impact the microbiota-gut-brain axis through modulation of the gut microbiota. Journal of Functional Foods. 2020;74:104176.
  4. Di Mauro A, Neu J, Riezzo G, et al. Gastrointestinal function development and microbiota. Ital J Pediatr. 2013;39:15.
  5. Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491-502.
  6. Cheng L, Akkerman R, Kong C, Walvoort MTC, de Vos P. More than sugar in the milk: human milk oligosaccharides as essential bioactive molecules in breast milk and current insight in beneficial effects. Crit Rev Food Sci Nutr. 2020:1-17.
  7. Salamone M, Di Nardo V. Effects of human milk oligosaccharides (HMOs) on gastrointestinal health. Front Biosci (Elite Ed). 2020;12:183-198.
  8. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012;3(1):4-14.
  9. Furness JB, Kunze WA, Clerc N. Nutrient tasting and signaling mechanisms in the gut. II. The intestine as a sensory organ: neural, endocrine, and immune responses. Am J Physiol. 1999;277(5):G922-928.
  10. Tanaka M, Nakayama J. Development of the gut microbiota in infancy and its impact on health in later life. Allergology International. 2017;66(4):515-522.
  11. Gensollen T, Iyer SS, Kasper DL, Blumberg RS. How colonization by microbiota in early life shapes the immune system. Science. 2016;352(6285):539-544.
  12. Zhao Q, Elson CO. Adaptive immune education by gut microbiota antigens. Immunology. 2018;154(1):28-37.
  13. Ni J, Friedman H, Boyd BC, et al. Early antibiotic exposure and development of asthma and allergic rhinitis in childhood. BMC Pediatr. 2019;19(1):225.
  14. Canova C, Zabeo V, Pitter G, et al. Association of maternal education, early infections, and antibiotic use with celiac disease: a population-based birth cohort study in northeastern Italy. Am J Epidemiol. 2014;180(1):76-85.
  15. Holscher HD, Davis SR, Tappenden KA. Human milk oligosaccharides influence maturation of human intestinal Caco-2Bbe and HT-29 cell lines. J Nutr. 2014;144(5):586-591.
  16. Yu ZT, Nanthakumar NN, Newburg DS. The Human Milk Oligosaccharide 2'-Fucosyllactose Quenches Campylobacter jejuni-Induced Inflammation in Human Epithelial Cells HEp-2 and HT-29 and in Mouse Intestinal Mucosa. J Nutr. 2016;146(10):1980-1990.
  17. Weichert S, Jennewein S, Hüfner E, et al. Bioengineered 2'-fucosyllactose and 3-fucosyllactose inhibit the adhesion of Pseudomonas aeruginosa and enteric pathogens to human intestinal and respiratory cell lines. Nutr Res. 2013;33(10):831-838.
  18. Azagra-Boronat I, Massot-Cladera M, Knipping K, et al. Oligosaccharides Modulate Rotavirus-Associated Dysbiosis and TLR Gene Expression in Neonatal Rats. Cells. 2019;8(8).
  19. Hester SN DS. Individual and combined effects of nucleotides and human milk oligosaccharides on proliferation, apoptosis, and necrosis in a human fetal intestinal cell line. Food and Nutrition Sciences. 2012;3:1567-1576.
  20. Stewart CJ, Ajami NJ, O'Brien JL, et al. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature. 2018;562(7728):583-588.
  21. Bezirtzoglou E, Tsiotsias A, Welling GW. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe. 2011;17(6):478-482.
  22. Turroni F, Milani C, Duranti S, et al. Bifidobacteria and the infant gut: an example of co-evolution and natural selection. Cell Mol Life Sci. 2018;75(1):103-118.
  23. Ruiz L, Delgado S, Ruas-Madiedo P, Sánchez B, Margolles A. Bifidobacteria and Their Molecular Communication with the Immune System. Front Microbiol. 2017;8:2345.
  24. Berger B, Porta N, Foata F, et al. Linking Human Milk Oligosaccharides, Infant Fecal Community Types, and Later Risk To Require Antibiotics. mBio. 2020;11(2).
  25. Ninonuevo MR, Park Y, Yin H, et al. A strategy for annotating the human milk glycome. J Agric Food Chem. 2006;54(20):7471-7480.
  26. Urashima T, Taufik E, Fukuda K, Asakuma S. Recent advances in studies on milk oligosaccharides of cows and other domestic farm animals. Biosci Biotechnol Biochem. 2013;77(3):455-466.
  27. Azad MB, Robertson B, Atakora F, et al. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices. J Nutr. 2018;148(11):1733-1742.
  28. Chaturvedi P, Warren CD, Altaye M, et al. Fucosylated human milk oligosaccharides vary between individuals and over the course of lactation. Glycobiology. 2001;11(5):365-372.
  29. Yu ZT, Chen C, Newburg DS. Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes. Glycobiology. 2013;23(11):1281-1292.
  30. Bode L, Jantscher-Krenn E. Structure-function relationships of human milk oligosaccharides. Adv Nutr. 2012;3(3):383s-391s.
  31. Goehring KC, Kennedy AD, Prieto PA, Buck RH. Direct evidence for the presence of human milk oligosaccharides in the circulation of breastfed infants. PLoS One. 2014;9(7):e101692.
  32. Geuking MB, Köller Y, Rupp S, McCoy KD. The interplay between the gut microbiota and the immune system. Gut Microbes. 2014;5(3):411-418.
  33. Fung TC, Olson CA, Hsiao EY. Interactions between the microbiota, immune and nervous systems in health and disease. Nat Neurosci. 2017;20(2):145-155.
  34. Vogt NM, Kerby RL, Dill-McFarland KA, et al. Gut microbiome alterations in Alzheimer's disease. Sci Rep. 2017;7(1):13537.
  35. Hopfner F, Künstner A, Müller SH, et al. Gut microbiota in Parkinson disease in a northern German cohort. Brain Res. 2017;1667:41-45.
  36. Pokusaeva K, Johnson C, Luk B, et al. GABA-producing Bifidobacterium dentium modulates visceral sensitivity in the intestine. Neurogastroenterol Motil. 2017;29(1).
  37. Williams BB, Van Benschoten AH, Cimermancic P, et al. Discovery and characterization of gut microbiota decarboxylases that can produce the neurotransmitter tryptamine. Cell Host Microbe. 2014;16(4):495-503.
  38. Suganya K, Koo BS. Gut-Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. Int J Mol Sci. 2020;21(20).

More than ingredients

Learn how DSM can help your business. Select the options below to connect your needs with the right solution.

I'd like to explore...

If the options above don't sound like you, skip ahead and contact us.

Quick Links

Food Specialties

Discover enzymes for baking, brewing, dairy and more.

Health Benefit Solutions

Solutions to address consumers' health and lifestyle needs.

Videos

Explore our products, services and solutions in our video library.

About DSM

Our purpose is to create brighter lives for all.

Talking Nutrition

Explore new science, consumer insights, industry events and more.

Webshop

Request samples, place orders and view product documentation.

This website uses cookies. We use cookies to personalize content and ads, to provide social media features and to analyze our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. You consent to our cookies if you continue to use our website.

Learn more